Similar articles

• Circulating thymulin and thymosin-alpha 1 activity in pediatric acquired immune deficiency syndrome: in vivo and in vitro studies.

  Rubinstein A, Novick BE, Sicklick MJ, Bernstein LJ, Incefy GS, Naylor PH, Goldstein AL. Rubinstein A, et al. J Pediatr. 1986 Sep;109(3):422-7. doi: 10.1016/s0022-3476(86)80111-1. J Pediatr. 1986. PMID: 3018210
• Thymosin in the early diagnosis and treatment of high risk homosexuals and hemophiliacs with AIDS-like immune dysfunction.

  Naylor PH, Schulof RS, Sztein MB, Spira TJ, McCurdy PR, Darr F, Kessler CM, Simon GL, Goldstein AL. Naylor PH, et al. Ann N Y Acad Sci. 1984;437:88-99. doi: 10.1111/j.1749-6632.1984.tb37125.x. Ann N Y Acad Sci. 1984. PMID: 6398657 Clinical Trial.
• Thymalfasin: an immune system enhancer for the treatment of liver disease.

  Sjogren MH. Sjogren MH. J Gastroenterol Hepatol. 2004 Dec;19(12):S69-72. J Gastroenterol Hepatol. 2004. PMID: 15641207 Review.
• Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application.

  Garaci E, Pica F, Rasi G, Favalli C. Garaci E, et al. Int J Immunopharmacol. 2000 Dec;22(12):1067-76. doi: 10.1016/s0192-0561(00)00075-8. Int J Immunopharmacol. 2000. PMID: 11137613 Review.
• Immunoreactive thymosin alpha 1 is associated with murine T-cell lymphomas.

  Zatz MM, McClure JE, Goldstein AL. Zatz MM, et al. Leuk Res. 1984;8(6):1003-10. doi: 10.1016/0145-2126(84)90054-7. Leuk Res. 1984. PMID: 6096635